IL22 and Alzheimer disease: By preferentially inhibiting JAK1, it disrupts signaling pathways mediated by key pro-inflammatory cytokines implicated in AD pathogenesis, such as IL-4, IL-13, IL-22, IL-31, and IFN-γ.